Predicting relapse in ulcerative colitis with early stool tests
Part of Digestive system clinical trials.
This study looks at whether early stool tests (fecal immunochemical test and calprotectin) can predict when ulcerative colitis symptoms might return. It is for people who have never taken biologic medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with ulcerative colitis, confirmed by a colonoscopy and biopsy.
- Your ulcerative colitis is moderately to severely active (Mayo score of 2 or higher on colonoscopy).
- You have never taken biologic drugs (like infliximab, adalimumab, vedolizumab, or ustekinumab) or JAK inhibitors.
- You have not used steroid medications (oral or IV) in the 4 weeks before starting the study.
- You are not taking blood thinners (like aspirin, clopidogrel, warfarin, or rivaroxaban) regularly.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at stool samples to see if certain markers can quickly tell whether a biologic medicine is starting to work for moderate-to-severe ulcerative colitis. If successful, this could help doctors make faster, smarter treatment decisions.
This study tests whether monitoring ulcerative colitis with stool-based markers—simple, non-invasive tests—can help guide treatment as effectively as the usual care approach. It aims to see if this strategy helps you stay in remission and avoid flare-ups.
This study looks at whether a simple stool test can tell if treatment is healing the gut lining in people with moderate to severe ulcerative colitis who are starting their first biologic medicine. If it works, this test might help doctors adjust treatment earlier.
This study tests a new way to monitor ulcerative colitis using stool tests and colonoscopy to detect early signs of cancer. It may help doctors manage long-term ulcerative colitis more safely.
This study looks at gut barrier function in people with ulcerative colitis who are in remission. It uses a non-invasive liver test to check for subtle changes in the body.
This trial compares how well different combinations of drugs calm inflammation in the gut compared to single drugs. It uses tissue samples taken during a colonoscopy to see which approach works best for people with inflammatory bowel disease.
Hear when a new FIT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.